Chugai Pharmaceutical Co Stock Performance
| CHGCY Stock | USD 20.69 0.17 0.83% |
The firm shows a Beta (market volatility) of 0.0279, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Chugai Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Chugai Pharmaceutical is expected to be smaller as well. At this point, Chugai Pharmaceutical has a negative expected return of -0.22%. Please make sure to confirm Chugai Pharmaceutical's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Chugai Pharmaceutical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Chugai Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 212.3 B | |
| Total Cashflows From Investing Activities | -118.9 B |
Chugai |
Chugai Pharmaceutical Relative Risk vs. Return Landscape
If you would invest 2,439 in Chugai Pharmaceutical Co on August 24, 2024 and sell it today you would lose (370.00) from holding Chugai Pharmaceutical Co or give up 15.17% of portfolio value over 90 days. Chugai Pharmaceutical Co is currently producing negative expected returns and takes up 2.582% volatility of returns over 90 trading days. Put another way, 22% of traded pink sheets are less volatile than Chugai, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Chugai Pharmaceutical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chugai Pharmaceutical's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Chugai Pharmaceutical Co, and traders can use it to determine the average amount a Chugai Pharmaceutical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0867
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CHGCY |
Estimated Market Risk
| 2.58 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Chugai Pharmaceutical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Chugai Pharmaceutical by adding Chugai Pharmaceutical to a well-diversified portfolio.
Chugai Pharmaceutical Fundamentals Growth
Chugai Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Chugai Pharmaceutical, and Chugai Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Chugai Pink Sheet performance.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.2 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 0.42 % | |||
| Current Valuation | 39.67 B | |||
| Shares Outstanding | 3.29 B | |||
| Price To Earning | 22.15 X | |||
| Price To Book | 4.62 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 999.76 B | |||
| EBITDA | 419.43 B | |||
| Cash And Equivalents | 545.3 B | |||
| Cash Per Share | 165.74 X | |||
| Total Debt | 16.04 B | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 432.94 X | |||
| Cash Flow From Operations | 279.63 B | |||
| Earnings Per Share | 0.86 X | |||
| Total Asset | 1.54 T | |||
| Retained Earnings | 500.19 B | |||
| Current Asset | 542.89 B | |||
| Current Liabilities | 107.7 B | |||
About Chugai Pharmaceutical Performance
Evaluating Chugai Pharmaceutical's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Chugai Pharmaceutical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Chugai Pharmaceutical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd. CHUGAI PHARMACEUTICAL operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 7664 people.Things to note about Chugai Pharmaceutical performance evaluation
Checking the ongoing alerts about Chugai Pharmaceutical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Chugai Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Chugai Pharmaceutical generated a negative expected return over the last 90 days | |
| Latest headline from businesswire.com: From The Dilenschneider Group Former MetroHealth CEO Dr. Akram Boutros Refiles Civil Damages Case |
- Analyzing Chugai Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Chugai Pharmaceutical's stock is overvalued or undervalued compared to its peers.
- Examining Chugai Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Chugai Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Chugai Pharmaceutical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Chugai Pharmaceutical's pink sheet. These opinions can provide insight into Chugai Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Chugai Pink Sheet Analysis
When running Chugai Pharmaceutical's price analysis, check to measure Chugai Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chugai Pharmaceutical is operating at the current time. Most of Chugai Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Chugai Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chugai Pharmaceutical's price. Additionally, you may evaluate how the addition of Chugai Pharmaceutical to your portfolios can decrease your overall portfolio volatility.